About: Peginesatide

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Peginesatide Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/drugbank/Drug, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	http://linked.opendata.cz/ontology/drugbank/Drug
http://linked.open...gbank/description	Peginesatide is a synthetic peptide attached to polyethylene glycol for the treatment of anemia. The polyethylene glycol moiety helps make the drug less immunogenic and prolongs its plasma half-life. Chemically, peginesatide is designed to mimic the pharmacological activity of erythropoietin, but is not a replica of the structure itself. Peginesatide consists of two 21-amino acid chains that are covalently bonded by a linker derived from iminodiacetic acid and β-alanine. FDA approved March 27, 2012. (en)
http://linked.open...generalReferences	# Schmid H: Peginesatide for the treatment of renal disease-induced anemia. Expert Opin Pharmacother. 2013 May;14(7):937-48. doi: 10.1517/14656566.2013.780695. Epub 2013 Mar 18. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/23506424 # Woodburn KW, Holmes CP, Wilson SD, Fong KL, Press RJ, Moriya Y, Tagawa Y: Absorption, distribution, metabolism and excretion of peginesatide, a novel erythropoiesis-stimulating agent, in rats. Xenobiotica. 2012 Jul;42(7):660-70. doi: 10.3109/00498254.2011.649310. Epub 2011 Dec 22. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/22188389 # Woodburn KW, Fong KL, Wilson SD, Sloneker S, Strzemienski P, Solon E, Moriya Y, Tagawa Y: Peginesatide clearance, distribution, metabolism, and excretion in monkeys following intravenous administration. Drug Metab Dispos. 2013 Apr;41(4):774-84. doi: 10.1124/dmd.112.048033. Epub 2013 Jan 14. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/23318685 (en)
http://linked.open...gy/drugbank/group	approved (en)
http://linked.open...drugbank/halfLife	IV dose, healthy subjects = 25.0 ± 7.6 hours; SubQ, healthy subjects = 53.0 ± 17.7 hours; IV dose, dialysis patients = 47.9 ± 16.5 hours; (en)
http://linked.open...ugbank/indication	Peginesatide is used for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis (en)
sameAs	Peginesatide
Title	Peginesatide (en)
adms:identifier	http://linked.opendata.cz/resource/drugbank/drug/DB08894/identifier/chebi/66895 http://linked.opendata.cz/resource/drugbank/drug/DB08894/identifier/drugbank/DB08894 http://linked.opendata.cz/resource/drugbank/drug/DB08894/identifier/kegg-drug/D09947 http://linked.opendata.cz/resource/drugbank/drug/DB08894/identifier/national-drug-code-directory/64764-620-20 http://linked.opendata.cz/resource/drugbank/drug/DB08894/identifier/wikipedia/Peginesatide
http://linked.open...mechanismOfAction	Peginesatide binds to and activates the human erythropoietin receptor and stimulates erythropoiesis in human red cell precursors in vitro. (en)
http://linked.open...y/drugbank/patent	http://linked.opendata.cz/resource/drugbank/patent/7084245 http://linked.opendata.cz/resource/drugbank/patent/7414105 http://linked.opendata.cz/resource/drugbank/patent/7528104 http://linked.opendata.cz/resource/drugbank/patent/7550433 http://linked.opendata.cz/resource/drugbank/patent/7919118 http://linked.opendata.cz/resource/drugbank/patent/7919461
http://linked.open...outeOfElimination	Peginesatide administered intravenously or subcutaneously is primarily excreted via urine. Most of the excreted dose is in the form of unchanged drug. Elimination from the plasma is biphasic and rapid from vascular compartments. In contrast, the drug is selectively retained in sites of erythropoiesis like the bone marrow. (en)
http://linked.open.../drugbank/synonym	Erythropoiesis-Stimulating Agent (ESA) (en) Hematide (en)
http://linked.open...drugbank/toxicity	The most common adverse events (≥10%) are dyspnea, diarrhea, nausea, cough, and arteriovenous fistula site complication. (en)
http://linked.open...umeOfDistribution	IV dose, dialysis patients = 34.9 ± 13.8 mL/kg; (en)
http://linked.open.../drug/hasAHFSCode	http://linked.opendata.cz/resource/AHFS/20-16%20
http://linked.open...nk/proteinBinding	Peginesatide does not bind to serum albumin or lipoprotein as demonstrated in in-vitro studies. (en)
http://linked.open...ogy/drugbank/salt	(en)
foaf:page	http://www.drugs.com/cdi/peginesatide.html http://www.rxlist.com/omontys-drug.htm
http://linked.open...Molecular-Formula	http://linked.opendata.cz/resource/drugbank/property/271B5B3B-363D-11E5-9242-09173F13E4C5
http://linked.open...logy/drugbank/pKa	http://linked.opendata.cz/resource/drugbank/property/271B5B3C-363D-11E5-9242-09173F13E4C5
http://linked.open...l/drug/hasATCCode	Peginesatide
http://linked.open...ugbank/absorption	Tmax, SubQ dose = 48 hours; Bioavailability, SubQ dose = 46%; Peginesatide does not accumulate when administered every 4 weeks following intravenous or subcutaneous administration. (en)
http://linked.open.../affectedOrganism	Humans and other mammals (en)
http://linked.open...casRegistryNumber	913976-27-9 (en)
http://linked.open...drugbank/category	(en)
http://linked.open...rugbank/clearance	Systemic clearance, IV dose, dialysis patients = 0.5 ± 0.2 mL/hr•kg (en)

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 112 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software